Literature DB >> 23480867

Long-term clinical outcomes of the one-stent technique versus the two-stent technique for non-left main true coronary bifurcation disease in the era of drug-eluting stents.

Yoon-Seok Koh1, Pum-Joon Kim, Kiyuk Chang, Hun-Jun Park, Myung-Ho Jeong, Hyo-Soo Kim, Yangsoo Jang, Hyeon-Cheol Gwon, Seung-Jung Park, Ki-Bae Seung.   

Abstract

BACKGROUND: Few studies have compared the long-term major adverse cardiac events (MACEs) between the one-stent technique (stenting only the main branch) and the two-stent technique (stenting of both the main and side branches) for the treatment of true coronary bifurcation lesions in the drug-eluting stent era. Therefore, we investigated this issue using the large nationwide coronary bifurcation registry.
METHODS: The 1,147 patients with non-left main coronary true bifurcation lesions underwent percutaneous coronary intervention in the Korea Coronary Bifurcation Stent (COBIS) registry. All patients were stratified based on the stent placement technique: one stent (n = 898) versus two stents (n = 249). MACE, including death, nonfatal myocardial infarction (MI), and repeat vessel and lesion revascularization (TVR and TLR), were evaluated.
RESULTS: The median follow-up duration was 20 months. The MACEs did not differ between the 2 groups. Findings from the one-stent group were similar to those of the two-stent group in composite of death, MI, or TVR, based on analysis by crude, multivariate Cox hazard regression model, inverse-probability-of-treatment weighting (hazard ratio [HR] 0.911, 95% confidence interval (CI) 0.614-1.351; HR 0.685 95% CI 0.381-1.232; HR 1.235, 95% CI 0.331-4.605, respectively). In further analysis with propensity score matching, the overall findings were consistent.
CONCLUSIONS: The findings of the present study indicate that the one-stent technique was not inferior to the two-stent technique for the treatment of non-left main true coronary bifurcation lesions in terms of long-term MACEs.
© 2013, Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2013        PMID: 23480867     DOI: 10.1111/joic.12025

Source DB:  PubMed          Journal:  J Interv Cardiol        ISSN: 0896-4327            Impact factor:   2.279


  6 in total

1.  Efficacy of one- vs. two-stent implantation for coronary bifurcation lesions in diabetic patients utilizing AIR2 as an endpoint.

Authors:  Zhizhong Liu; Guozhen Jin; Yuzhen Qi; Shoujie Shan; Junjie Zhang; Fei Ye; Nailiang Tian; Jiupei Chen; Shaoliang Chen
Journal:  Int J Clin Exp Med       Date:  2015-07-15

2.  DK mini-culotte stenting in the treatment of true coronary bifurcation lesions: a propensity score matching comparison with T-provisional stenting.

Authors:  Lin Fan; Lianglong Chen; Yukun Luo; Linlin Zhang; Wenliang Zhong; Chaogui Lin; Zhaoyang Chen; Yafei Peng; Xingchun Zhen; Xianfeng Dong
Journal:  Heart Vessels       Date:  2014-12-17       Impact factor: 2.037

3.  Randomized Comparison of the Crush Versus the Culotte Stenting for Coronary Artery Bifurcation Lesions.

Authors:  Xu-Wei Zheng; Dong-Hui Zhao; Hong-Yu Peng; Qian Fan; Qin Ma; Zhen-Ye Xu; Chao Fan; Li-Yu Liu; Jing-Hua Liu
Journal:  Chin Med J (Engl)       Date:  2016-03-05       Impact factor: 2.628

4.  Optimal Revascularization Strategy on Medina 0,1,0 Left Main Bifurcation Lesions in Type 2 Diabetes.

Authors:  Xuwei Zheng; Hongyu Peng; Donghui Zhao; Qin Ma; Kun Fu; Guo Chen; Qian Fan; Jinghua Liu
Journal:  J Diabetes Res       Date:  2016-09-29       Impact factor: 4.011

5.  A wide-angle lens to focus on coronary bifurcational lesions.

Authors:  Flavio Airoldi; Luca Paolo Alberti; Davide Tavano
Journal:  Int J Cardiol Heart Vasc       Date:  2022-03-05

6.  Effect of Stenting Strategy on the Outcome in Patients with Non-Left Main Bifurcation Lesions.

Authors:  Yongwhan Lim; Min Chul Kim; Youngkeun Ahn; Doo Sun Sim; Young Joon Hong; Ju Han Kim; Myung Ho Jeong; Hyeon-Cheol Gwon; Hyo-Soo Kim; Seung Woon Rha; Jung Han Yoon; Yangsoo Jang; Seung-Jea Tahk; Ki Bae Seung
Journal:  J Clin Med       Date:  2022-09-26       Impact factor: 4.964

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.